INVEGA SUSTENNA® (paliperidone palmitate)

FOR US HEALTHCARE PROFESSIONALS ONLY

Patient survey results

The treatment of schizophrenia continues to evolve, and so do our patients’ views on the treatment options available to them. Contrary to some previous assumptions, insights from the Choices and Voices™ Patient Survey involving 200 adult patients with schizophrenia showed a strong preference to engage in discussions about LAIs, and to have those conversations earlier in their treatment.*

This survey included adult patients currently on an oral antipsychotic, adult patients currently on an LAI, and patients who have previously been on an LAI. 

Interest in longer
dosing intervals

Even if they were stable on their current daily oral antipsychotic medication, 92% of adults with schizophrenia would like their HCP to recommend an LAI if they felt it was the best treatment option.^1†‡

Open to
injections

91% of adult patients on a daily oral antipsychotic schizophrenia medication said they would like their HCP to recommend a long-acting medication, and remained open to the idea after finding out it is an injection.^1†§

Interest in
earlier initiation

Now knowing what it’s like to live with schizophrenia, 90% of adult patients currently on an LAI said they wished they would have started an LAI sooner after diagnosis.^1†||

The longest
dosing intervals

Of adult patients on daily oral medication for schizophrenia who were open to HCP recommendation of any LAI, 94% said they would prefer to move beyond the once-a-month injection to a 3- or 6-month injection vs staying on the once-monthly option.^1†¶

Awareness
of LAIs

81% of recently diagnosed adults with schizophrenia would like their HCP to discuss all dosing options with them, including medications that last 1, 3, or 6 months per dose, when determining initial treatment after diagnosis.^1†#

The importance
of adherence

Of adult patients taking a daily oral antipsychotic medication, 82% believe it is less important to take their medication daily once their symptoms become less noticeable.^1†**

Get real-world strategies from top medical professionals on how to effectively discuss LAIs with your patients

HCP=healthcare provider; LAI=long-acting injectable.

*The Choices and Voices™ Patient Survey included a diverse sample of 200 adult patients with schizophrenia, aged 18-60, who were diagnosed within the last 20 years, and currently on treatment.¹ 

†Based on results from a survey of randomly selected adult patients with schizophrenia (N=200).

‡A subgroup of adult patients with schizophrenia were current users of daily oral antipsychotics (n=151), and among those users, 92% (n=139/151) indicated they would like their healthcare provider to recommend a long-acting medication even if they were stable on their current medication.

§A subgroup of adult patients with schizophrenia who were daily oral users (n=151), and among those users, 91% (n=137/151) indicated they would like their healthcare provider to recommend a long-acting medication and remained open after finding out it is an injection.

||A subgroup of patients were current LAI users (n=49), and among those patients, 90% (n=44/49) agreed strongly, mostly, or somewhat (on a 7-point scale) that now knowing what schizophrenia is like, they wish they had started an LAI sooner after their diagnosis.

¶A subgroup of patients were daily oral antipsychotic users who were open to HCP recommendation of any LAI option (n=140), and among those patients, 94% (n=132/140) indicated that they would prefer to move from a 1-month option to a 3- or 6-month option vs remaining on the 1-month option.

#A subgroup of adult patients with schizophrenia were diagnosed in the past 5 years (n=180). Among those users, 81%, (n=146/180) indicated they would like their healthcare provider to discuss all dosing options with them at the time of diagnosis.

**A subgroup of patients were on daily oral antipsychotic medication (n=151), and among those, 82% (n=124/151) agreed strongly, mostly, or somewhat (on a 7-point scale) that they felt it was less important to take their daily oral medication when their symptoms become less noticeable.

Reference: 1. Data on file. Janssen Pharmaceuticals, Inc.